Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs42
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials25
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing18
A Landscape Assessment of Key Evidence Needs in Study Design and Statistical Methodologies for HTA Submissions18
Considerations on Interim Evaluation of OS in Pivotal Oncology Trials17
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data16
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies14
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility13
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints12
The Current Landscape of HTA Framework and Key Challenges11
An Enhanced Doubly Robust Causal Estimator for Nonrandomized Trials with Binary Outcome11
0.18246102333069